Johnson & Johnson (NYSE:JNJ) Stock Price Up 3.8% – What’s Next?

by · The Markets Daily

Johnson & Johnson (NYSE:JNJ – Get Free Report)’s share price rose 3.8% on Thursday. The stock traded as high as $269.67 and last traded at $267.6680. 9,712,091 shares were traded during trading, an increase of 21% from the average session volume of 8,006,106 shares. The stock had previously closed at $257.78.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

  • Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J’s oral psoriasis pill
  • Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data
  • Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers
  • Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment
  • Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed
  • Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. Royal Bank Of Canada decreased their target price on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. The Goldman Sachs Group restated a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Citigroup upped their price target on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Sanford C. Bernstein set a $270.00 price objective on Johnson & Johnson in a report on Thursday, October 15th. Finally, Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Check Out Our Latest Analysis on JNJ

Johnson & Johnson Stock Down 1.3%

The company’s fifty day moving average price is $265.64 and its 200-day moving average price is $250.21. The stock has a market capitalization of $635.85 billion, a PE ratio of 40.02, a price-to-earnings-growth ratio of 2.65 and a beta of 0.21. The company has a quick ratio of 0.81, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is currently 81.21%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 64,515 shares of company stock valued at $17,271,766 in the last quarter. 0.16% of the stock is owned by insiders.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors and hedge funds have recently made changes to their positions in the company. Access Investment Management LLC increased its position in Johnson & Johnson by 12.2% during the third quarter. Access Investment Management LLC now owns 5,659 shares of the company’s stock valued at $1,498,000 after acquiring an additional 615 shares during the last quarter. Tower View Wealth Management LLC lifted its holdings in Johnson & Johnson by 74.6% in the third quarter. Tower View Wealth Management LLC now owns 1,660 shares of the company’s stock valued at $439,000 after acquiring an additional 709 shares during the period. Pullen Investment Management LLC boosted its position in Johnson & Johnson by 0.7% in the third quarter. Pullen Investment Management LLC now owns 6,959 shares of the company’s stock worth $1,842,000 after purchasing an additional 46 shares during the last quarter. Leeward Financial Partners LLC purchased a new position in Johnson & Johnson in the third quarter worth about $201,000. Finally, Sigma Planning Corp grew its stake in shares of Johnson & Johnson by 7.5% during the 3rd quarter. Sigma Planning Corp now owns 66,705 shares of the company’s stock valued at $17,549,000 after purchasing an additional 4,676 shares during the period. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

See Also